NutriSteppe Digital Dietary Intervention / Overweight / Type 2 Diabetes Mellitus (T2DM) · Interventional Study

Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy

ClinicalTrials.gov · August 11, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a planned randomized controlled trial comparing a digital dietary intervention (NutriSteppe) plus routine care versus routine care alone in adults with type 2 diabetes or obesity already receiving GLP-1 receptor agonist therapy. The study is currently recruiting and has not yet reported primary outcome data.

What was studied

Interventional, Randomized, Parallel, Open label, Other purpose. Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder), Overweight, Metabolic Syndrome; age from 21 Years; to 65 Years. Intervention: NutriSteppe Intervention Group. Compared with: Control Group — No Intervention. n = 120. 1 site: Kazakhstan.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a registry record for an ongoing interventional study with no reported results; enrollment is active and primary outcome data at 12 weeks have not yet been posted.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 (assessed at Baseline and Week 12)

DesignInterventional, Randomized, Parallel, Open label, Other purpose

PopulationType 2 Diabetes Mellitus (T2DM), Obesity (Disorder), Overweight, Metabolic Syndrome; age from 21 Years; to 65 Years

Sample size120

InterventionNutriSteppe Intervention Group

ComparatorControl Group — No Intervention

Setting1 site: Kazakhstan

Reported figures

Quoted from the source exactly as published.

Planned sample size120

Primary outcome measureChange from baseline in HbA1c at Week 12

Study duration12 weeks

Caveats

No results have been posted in this registry record; primary outcome data are not yet available.
Phase designation listed as 'NA', limiting clarity on trial stage and design rigor.
Blinding strategy and allocation concealment procedures not described in registry record.
Secondary outcomes (fasting glucose, weight, lipids, blood pressure, diet quality, quality of life) noted but no effect measures reported.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Randomized controlled trial with two parallel arms, but phase not specified.

Directness

strong

Primary outcome is HbA1c, a direct measure of glycemic control in T2DM.

Consistency

insufficient

No results reported; consistency cannot be assessed against other evidence.

Risk of bias

insufficient

Blinding status and allocation concealment details not stated in registry record.

Sample adequacy

limited

Estimated enrollment 120 participants; adequacy for primary endpoint unclear.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07728669). This is a study registration, not published results. Lead sponsor: Kazakh Academy of Nutrition. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 120 participants (ESTIMATED). Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity (Disorder), Overweight, Metabolic Syndrome. Interventions: BEHAVIORAL: NutriSteppe Digital Dietary Intervention. Primary outcome measures: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 , Baseline and Week 12. Brief summary: The goal of this clinical trial is to learn whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years with type 2 diabetes mellitus, obesity, or overweight with related health conditions. Participants are already receiving or have been prescribed glucagon-like peptide-1 (GLP-1) receptor agonist therapy by their treating physicians outside the study. The main question is: Does the NutriSteppe digital dietary intervention improve glycated hemoglobin (HbA1c), a measure of average blood glucose, after 12 weeks compared with routine medical care alone? The study will also assess changes in fasting blood glucose, body weight, body mass index, waist circumference, cholesterol, triglycerides, blood pressure, diet quality, quality of life, dietary adherence, and safety. Researchers will randomly assign participants to one of two groups. The control group will continue routine medical care and receive general lifestyle advice. The intervention group will continue routine medical care and use the NutriSteppe application for 12 weeks to receive personalized dietary support. Participants in both groups will: * Attend study visits and complete the examinations, laboratory tests, and questionnaires specified in the study protocol. * Photograph everything they eat and drink. * Have their food photographs automatically analyzed using Tagam-AI, a system developed for this study. * Be able to view the results of the food photograph analysis. The photography and automated analysis procedures will be the same in both groups. Only participants in the intervention group will receive personalized dietary recommendations generated from these data through the NutriSteppe application.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NutriSteppe Digital Dietary InterventionOverweightType 2 Diabetes Mellitus (T2DM)Kazakh Academy of NutritionNCT07728669Obesity (disorder)